Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.